Cancer treatment methods must meet rigorous constraints before being approved by the FDA for administration to patients. Consequently, it is estimated that in 2012, more than 50% of the diagnosed cancer cases died worldwide due to these constraints preventing usage and treatment. It is becoming increasingly important to present more options for cancer treatment, and improve on existing methods to increase the likelihood of FDA acceptance.
Taking advantage of an FDA-approved substance, this technology led to 75% suppression in tumor growth in an orthotopic pancreatic cancer model. Pending analysis includes testing the anti-metastasis effects of this technology in the animal models.
Reference Number: D-1409
Features, Benefits, & Advantages:
Repurposes an existing drug
Capable of crossing the blood-brain barrier
Limited known side effects
A US provisional patent, serial number 62585080, was filed on 11/13/17.
Development Stage: The method has been developed and tested in animal models.
Sanjay Srivastava, Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Amarillo, Texas
Sharavan Ramachandra, Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas
Keywords: Cancer, anticancer, antipsychotic